EMEA-002239-PIP02-21
EMEA-002239-PIP02-21
EMEA-002239-PIP02-21
Opinion/decision on a Paediatric investigation plan (PIP): Tavlesse, Fostamatinib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Haematology-Hemostaseology;Immunology-Rheumatology-Transplantation, PIP number: P/0027/2022
Opinion/decision on a Paediatric investigation plan (PIP): Alecensa, Alectinib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Oncology, PIP number: P/0006/2022
Proline - Scientific guideline
EMEA-002839-PIP01-20-M01
EMEA-002700-PIP01-19-M01
Blenrep : EPAR - Public assessment report
Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, from 22 January 2024, 10:00 (CET) to 22 January 2024, 13:30 (CET)
Innovation Task Force (ITF) briefing meeting request form
Paediatric Committee (PDCO): 16-19 January 2024, European Medicines Agency, Amsterdam, the Netherlands, from 16 January 2024 to 19 January 2024